Stryker stock trades at EUR 247.85 with a 28.8 P/ E ratio

Published on 10/09/2026 at 20:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 6.59 billion, up 9.4 percent year over year. Stryker stock costs EUR 247.85 on October 9, 2026 versus EUR 246.85.

Key points in brief

Stryker stock traded at EUR 247.85 at Lang & Schwarz on October 9, 2026, up 0.41 percent versus EUR 246.85.
The stock carried a 28.8 P/E ratio, while second-quarter revenue rose 9.4 percent year over year to USD 6.59 billion.
Stryker's NYSE market capitalization was USD 106.4 billion, and the next earnings date was October 29, 2026.
Boston Scientific and Medtronic showed daily gains of 0.57 percent and 0.61 percent, respectively, on October 9, 2026.

Pop-Art-Comic zeigt Chirurgen mit robotergestütztem OP-System in leuchtenden Farben — Pop-Art-Comic-Illustration einer farbenfrohen Roboterchirurgie-Szene verbildlicht anschaulich das Geschäftsfeld von Stryker Corp. US8636671013 heute, Illustration mit AI erstellt.

Stryker Corp. stock (ISIN US8636671013) was trading at EUR 247.85 at Lang & Schwarz on October 9, 2026 at 8:18 p.m. CEST, plus 0.41 percent versus the prior close of EUR 246.85. The 28.8 P/E ratio puts valuation at the center of the market report, while the latest operating figures show continued sales growth.

Price holds after-hours level

The US-listed medical-device maker was last at USD 277.47 on the NYSE on October 9, 2026 at 2:19 p.m. ET. The same quotation showed a 52-week range of USD 267.00 to USD 392.55, leaving the price 29.31 percent below the high.

Lang & Schwarz showed a bid of EUR 247.50 and an ask of EUR 248.20 at 8:18 p.m. CEST. Stryker's EUR 247.85 price therefore stood EUR 1.00 above the prior close, a smaller move than the 9.4 percent second-quarter revenue increase reported by the company.

Revenue growth meets execution risk

According to Yahoo Finance, Stryker generated USD 6.59 billion of revenue in the second quarter of 2026, up 9.4 percent from the second quarter of 2025. Adjusted earnings per share rose 17.9 percent to USD 3.69, while adjusted operating margin expanded to 27.4 percent from the comparable period.

The same second-quarter call set full-year 2026 adjusted earnings-per-share guidance at USD 14.95 to USD 15.10 and organic net sales growth guidance at 8.3 percent to 9.3 percent. The guidance is important for the next valuation step because the company is balancing production recovery, demand for capital equipment and a supply disruption in Peripheral Vascular.

Comparison with peers on October 9, 2026

Stryker Corp.: plus 0.41 percent, P/E 28.8, market capitalization USD 106.4 billion

Boston Scientific (NYSE, USD): plus 0.57 percent, P/E 17.2, market capitalization USD 62.8 billion

Medtronic (NYSE, USD): plus 0.61 percent, P/E 21.8, market capitalization USD 113.0 billion

Next earnings date is October 29

Gekko lists October 29, 2026, after the market close, as Stryker's next earnings date. Its estimate calls for third-quarter revenue of USD 6.63 billion and earnings per share of USD 3.56, creating a concrete test for the company's 8.3 percent to 9.3 percent full-year organic growth outlook.

Valuation remains the market marker

At USD 106.4 billion, Stryker's market capitalization is below Medtronic's USD 113.0 billion but above Boston Scientific's USD 62.8 billion. The comparison places Stryker's 28.8 P/E ratio above both peers' ratios of 21.8 and 17.2, while the upcoming results provide the next dated operating checkpoint.

For investors in Germany, the key figures are the EUR 247.85 after-hours quote, the plus 0.41 percent move versus EUR 246.85 and the 29.31 percent gap to the NYSE 52-week high in US dollars. The further course of trading is shown by the continuously updated real-time quote of Stryker stock.